SG11201601230RA - Pharmaceutical compositions comprising macrolide diastereomers, methods of their synthesis and therapeutic uses - Google Patents
Pharmaceutical compositions comprising macrolide diastereomers, methods of their synthesis and therapeutic usesInfo
- Publication number
- SG11201601230RA SG11201601230RA SG11201601230RA SG11201601230RA SG11201601230RA SG 11201601230R A SG11201601230R A SG 11201601230RA SG 11201601230R A SG11201601230R A SG 11201601230RA SG 11201601230R A SG11201601230R A SG 11201601230RA SG 11201601230R A SG11201601230R A SG 11201601230RA
- Authority
- SG
- Singapore
- Prior art keywords
- synthesis
- methods
- pharmaceutical compositions
- therapeutic uses
- macrolide
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
- A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361869954P | 2013-08-26 | 2013-08-26 | |
US201461934313P | 2014-01-31 | 2014-01-31 | |
PCT/US2014/052757 WO2015031396A1 (en) | 2013-08-26 | 2014-08-26 | Pharmaceutical compositions comprising macrolide diastereomers, methods of their synthesis and therapeutic uses |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201601230RA true SG11201601230RA (en) | 2016-03-30 |
Family
ID=51542449
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201601230RA SG11201601230RA (en) | 2013-08-26 | 2014-08-26 | Pharmaceutical compositions comprising macrolide diastereomers, methods of their synthesis and therapeutic uses |
Country Status (17)
Country | Link |
---|---|
US (3) | US20160354482A1 (es) |
EP (1) | EP3038624A1 (es) |
JP (1) | JP6608823B2 (es) |
KR (1) | KR102252925B1 (es) |
CN (1) | CN105530942B (es) |
AU (1) | AU2014311361B2 (es) |
BR (1) | BR112016004023A2 (es) |
CA (1) | CA2921412A1 (es) |
CL (1) | CL2016000408A1 (es) |
EA (1) | EA038192B1 (es) |
HK (1) | HK1220115A1 (es) |
IL (1) | IL244203B (es) |
MX (1) | MX2016002149A (es) |
PH (1) | PH12016500380A1 (es) |
SG (1) | SG11201601230RA (es) |
WO (1) | WO2015031396A1 (es) |
ZA (1) | ZA201601534B (es) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MY183572A (en) | 2013-03-15 | 2021-02-26 | Regeneron Pharma | Biologically active molecules, conjugates thereof, and therapeutic uses |
EA038192B1 (ru) | 2013-08-26 | 2021-07-21 | Регенерон Фармасьютикалз, Инк. | Фармацевтические композиции, содержащие диастереомеры макролида, способы их синтезирования и терапевтическое применение |
WO2016160615A1 (en) * | 2015-03-27 | 2016-10-06 | Regeneron Pharmaceuticals, Inc. | Maytansinoid derivatives, conjugates thereof, and methods of use |
CA2987641A1 (en) | 2015-07-06 | 2017-01-12 | Regeneron Pharmaceuticals, Inc. | Multispecific antigen-binding molecules and uses thereof |
EA039072B9 (ru) | 2016-01-25 | 2022-02-04 | Регенерон Фармасьютикалз, Инк. | Производные майтанзиноида, их конъюгаты и способы применения |
WO2017190079A1 (en) | 2016-04-28 | 2017-11-02 | Regeneron Pharmaceuticals, Inc. | Methods of making multispecific antigen-binding molecules |
US10738130B2 (en) | 2016-09-23 | 2020-08-11 | Regeneron Pharmaceuticals, Inc. | Bispecific antigen-binding molecules that bind MUC16 and CD3, and compositions thereof |
EP3515945A1 (en) | 2016-09-23 | 2019-07-31 | Regeneron Pharmaceuticals, Inc. | Anti-steap2 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind steap2 and cd3, and uses thereof |
TWI782930B (zh) * | 2016-11-16 | 2022-11-11 | 美商再生元醫藥公司 | 抗met抗體,結合met之雙特異性抗原結合分子及其使用方法 |
WO2018102304A1 (en) | 2016-11-29 | 2018-06-07 | Regeneron Pharmaceuticals, Inc. | Methods of treating prlr positive breast cancer |
US11491237B2 (en) | 2017-05-18 | 2022-11-08 | Regeneron Pharmaceuticals, Inc. | Cyclodextrin protein drug conjugates |
MX2020004691A (es) | 2017-11-07 | 2020-08-20 | Regeneron Pharma | Enlazadores hidrofilicos para conjugados anticuerpo-farmaco. |
CN112074538A (zh) | 2018-04-30 | 2020-12-11 | 瑞泽恩制药公司 | 结合her2和/或aplp2的抗体和双特异性抗原结合分子、其缀合物和用途 |
BR112020023145A2 (pt) | 2018-05-17 | 2021-02-02 | Regeneron Pharmaceuticals, Inc. | anticorpo anti-cd63 ou fragmento de ligação ao antígeno do mesmo, molécula de ligação ao antígeno biespecífica, proteína terapêutica de múltiplos domínios, polinucleotídeo composição farmacêutica, e, composto |
MX2021010114A (es) | 2019-02-21 | 2021-12-10 | Regeneron Pharma | Métodos para tratar el cáncer ocular mediante el uso de anticuerpos anti-met y moléculas de unión a antígeno bispecíficas que se unen a met. |
EP4031574A1 (en) | 2019-09-16 | 2022-07-27 | Regeneron Pharmaceuticals, Inc. | Radiolabeled met binding proteins for immuno-pet imaging |
US11814428B2 (en) | 2019-09-19 | 2023-11-14 | Regeneron Pharmaceuticals, Inc. | Anti-PTCRA antibody-drug conjugates and uses thereof |
US20220387618A1 (en) | 2019-11-15 | 2022-12-08 | Seagen Inc. | Methods of treating her2 positive breast cancer with tucatinib in combination with an anti-her2 antibody-drug conjugate |
WO2021174113A1 (en) | 2020-02-28 | 2021-09-02 | Regeneron Pharmaceuticals, Inc. | Bispecific antigen binding molecules that bind her2, and methods of use thereof |
WO2021211984A1 (en) | 2020-04-16 | 2021-10-21 | Regeneron Pharmaceuticals, Inc. | Diels-alder conjugation methods |
JP2023534437A (ja) | 2020-07-13 | 2023-08-09 | リジェネロン ファーマシューティカルズ,インク. | タンパク質中のグルタミン残基にコンジュゲートされたカンプトテシンアナログおよびその使用 |
IL301702A (en) | 2020-10-22 | 2023-05-01 | Regeneron Pharma | Anti-FGFR2 antibodies and methods of using them |
KR20230107261A (ko) | 2020-11-10 | 2023-07-14 | 리제너론 파마슈티칼스 인코포레이티드 | 셀레늄 항체 접합물 |
CN115215780B (zh) * | 2022-04-22 | 2023-08-08 | 上海格苓凯生物科技有限公司 | 一种利用n,n-二琥珀酰亚胺基碳酸酯制备异双功能交联剂smcc的方法 |
Family Cites Families (69)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4307016A (en) | 1978-03-24 | 1981-12-22 | Takeda Chemical Industries, Ltd. | Demethyl maytansinoids |
JPS5566585A (en) | 1978-11-14 | 1980-05-20 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
CA2026147C (en) | 1989-10-25 | 2006-02-07 | Ravi J. Chari | Cytotoxic agents comprising maytansinoids and their therapeutic use |
US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
US5714586A (en) | 1995-06-07 | 1998-02-03 | American Cyanamid Company | Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates |
US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
US20070258987A1 (en) | 2000-11-28 | 2007-11-08 | Seattle Genetics, Inc. | Recombinant Anti-Cd30 Antibodies and Uses Thereof |
EP1258255A1 (en) | 2001-05-18 | 2002-11-20 | Boehringer Ingelheim International GmbH | Conjugates of an antibody to CD44 and a maytansinoid |
US20090068178A1 (en) * | 2002-05-08 | 2009-03-12 | Genentech, Inc. | Compositions and Methods for the Treatment of Tumor of Hematopoietic Origin |
US8088387B2 (en) | 2003-10-10 | 2012-01-03 | Immunogen Inc. | Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates |
US7276497B2 (en) | 2003-05-20 | 2007-10-02 | Immunogen Inc. | Cytotoxic agents comprising new maytansinoids |
US7628986B2 (en) | 2003-06-27 | 2009-12-08 | Amgen Fremont Inc. | Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof |
GB0316294D0 (en) | 2003-07-11 | 2003-08-13 | Polytherics Ltd | Conjugated biological molecules and their preparation |
TW200539855A (en) | 2004-03-15 | 2005-12-16 | Wyeth Corp | Calicheamicin conjugates |
MXPA06014065A (es) | 2004-06-01 | 2007-01-31 | Genentech Inc | Conjugados de droga-anticuerpo y metodos. |
CA2587589A1 (en) | 2004-11-29 | 2006-06-22 | Seattle Genetics, Inc. | Engineered antibodies and immunoconjugates |
PL1819359T3 (pl) | 2004-12-09 | 2015-08-31 | Janssen Biotech Inc | Immunokoniugaty skierowane przeciw integrynie, metody ich wytwarzania oraz ich zastosowanie |
US7750116B1 (en) | 2006-02-18 | 2010-07-06 | Seattle Genetics, Inc. | Antibody drug conjugate metabolites |
LT2845866T (lt) | 2006-10-27 | 2017-07-10 | Genentech, Inc. | Antikūnai ir imunokonjugatai bei jų panaudojimas |
WO2008122039A2 (en) | 2007-04-02 | 2008-10-09 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Selenocysteine mediated hybrid antibody molecules |
US7723485B2 (en) | 2007-05-08 | 2010-05-25 | Genentech, Inc. | Cysteine engineered anti-MUC16 antibodies and antibody drug conjugates |
DK2167963T3 (da) | 2007-05-23 | 2019-06-24 | Ventana Med Syst Inc | Polymerbærere til immunhistokemi og in situ-hybridisering |
EP3692988A3 (en) * | 2008-03-18 | 2020-10-14 | Genentech, Inc. | Combinations of an anti-her2 antibody-drug conjugate and 5-fu, anti-vegf antibody, carboplatin or abt-869 and methods of use |
BRPI0911442A2 (pt) | 2008-04-30 | 2019-03-12 | Immunogen, Inc. | conjugados potentes e ligantes hidrofílicos |
US8969626B2 (en) | 2008-07-21 | 2015-03-03 | Polytherics Limited | Reagents and method for conjugating biological molecules |
US9005598B2 (en) | 2009-03-04 | 2015-04-14 | Polytherics Limited | Conjugated proteins and peptides |
JP2013501766A (ja) | 2009-08-10 | 2013-01-17 | ユーシーエル ビジネス パブリック リミテッド カンパニー | 固体基材の官能化 |
AR078471A1 (es) | 2009-10-02 | 2011-11-09 | Sanofi Aventis | COMPUESTOS MAITANSINOIDES Y EL USO DE ESTOS PARA PREPARAR CONJUGADOS CON UN ANTICUERPO LOS CUALES SE UTILIZAN COMO AGENTES ANTICANCERIGENOS Y EL PROCEDIMIENTO DE PREPARACIoN DE ESTOS CONJUGADOS |
TW201116297A (en) | 2009-10-02 | 2011-05-16 | Sanofi Aventis | Antibodies that specifically bind to the EphA2 receptor |
IN2012DN02780A (es) * | 2009-10-06 | 2015-09-18 | Immunogen Inc | |
US8501692B2 (en) | 2009-12-14 | 2013-08-06 | The Regents Of The University Of Michigan | Compositions and methods for altering cocaine esterase activity |
SI2528625T1 (sl) | 2010-04-15 | 2013-11-29 | Spirogen Sarl | Pirolobenzodiazepini in njihovi konjugati |
US20130244905A1 (en) | 2010-07-06 | 2013-09-19 | Ed Grabczyk | Reporter for RNA Polymerase II Termination |
NZ606824A (en) | 2010-08-02 | 2015-05-29 | Regeneron Pharma | Mice that make binding proteins comprising vl domains |
MX339739B (es) | 2010-09-01 | 2016-06-07 | Bayer Ip Gmbh | N-(tetrazol-5-il)-y n-(triazol-5-il)arilcarboxamidas y su uso como herbicidas. |
CN103328505B (zh) | 2010-10-29 | 2015-12-02 | 伊缪诺金公司 | 非拮抗性egfr结合分子及其免疫偶联物 |
BR112013010853A2 (pt) | 2010-11-03 | 2016-08-16 | Immunogen Inc | "agentes citotóxicos compreendendo derivados de ansamitocina, composição farmacêutica e uso destes" |
ES2920373T3 (es) | 2011-05-16 | 2022-08-03 | Tagworks Pharmaceuticals B V | Activación de fármaco bioortogonal |
MX371526B (es) | 2011-05-27 | 2020-01-31 | Ambrx Inc | Composiciones que contienen, metodos que incluyen, y usos de derivados de dolastatina enlazados a aminoacidos no naturales. |
US8815226B2 (en) | 2011-06-10 | 2014-08-26 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates |
BR112013032928A2 (pt) | 2011-06-21 | 2017-01-24 | Immunogen Inc | "derivados de maitansinoide com ligante de peptídeo e conjugados dos mesmos, composição farmacêutica que os compreende e uso dos mesmos" |
EA026643B1 (ru) | 2011-10-14 | 2017-04-28 | Сиэтл Дженетикс, Инк. | Пирролбензодиазепины и конъюгаты направленного действия |
WO2013053873A1 (en) | 2011-10-14 | 2013-04-18 | Spirogen Sàrl | Pyrrolobenzodiazepines |
EP2751076B1 (en) | 2011-10-14 | 2018-04-25 | MedImmune Limited | Synthesis method and intermediates useful in the preparation of pyrrolobenzodiazepines |
EP2755642B1 (en) | 2011-10-14 | 2018-07-18 | Seattle Genetics, Inc. | Pyrrolobenzodiazepines and targeted conjugates |
WO2013068874A1 (en) | 2011-11-11 | 2013-05-16 | Pfizer Inc. | Antibody-drug conjugates |
WO2013085925A1 (en) | 2011-12-05 | 2013-06-13 | Igenica, Inc. | Antibody-drug conjugates and related compounds, compositions, and methods |
GB201210770D0 (en) | 2012-06-18 | 2012-08-01 | Polytherics Ltd | Novel conjugation reagents |
IN2014DN10428A (es) | 2012-06-19 | 2015-08-21 | Polytherics Ltd | |
EP2911699B1 (en) | 2012-10-23 | 2017-11-15 | SynAffix B.V. | Modified antibody, antibody-conjugate and process for the preparation thereof |
NO2789793T3 (es) | 2012-10-24 | 2018-01-27 | ||
AU2012395148B2 (en) | 2012-11-24 | 2016-10-27 | Hangzhou Dac Biotech Co., Ltd. | Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules |
TW201425336A (zh) * | 2012-12-07 | 2014-07-01 | Amgen Inc | Bcma抗原結合蛋白質 |
CN103254213B (zh) | 2012-12-21 | 2015-02-25 | 百奥泰生物科技(广州)有限公司 | 类美登素酯的制备方法及用于所述方法的组合物 |
CN104688740A (zh) | 2012-12-21 | 2015-06-10 | 百奥泰生物科技(广州)有限公司 | 类美登素衍生物及其制备方法和用途 |
MY183572A (en) | 2013-03-15 | 2021-02-26 | Regeneron Pharma | Biologically active molecules, conjugates thereof, and therapeutic uses |
CN103254311B (zh) * | 2013-05-09 | 2015-05-13 | 齐鲁制药有限公司 | 一种制备抗体-美登素类生物碱药物偶联物的方法 |
WO2014194030A2 (en) | 2013-05-31 | 2014-12-04 | Immunogen, Inc. | Conjugates comprising cell-binding agents and cytotoxic agents |
US11229711B2 (en) | 2013-06-06 | 2022-01-25 | Magenta Therapeutics, Inc. | Linkers for antibody-drug conjugates and related compounds, compositions, and methods of use |
WO2014197866A1 (en) | 2013-06-06 | 2014-12-11 | Igenica Biotherapeutics, Inc. | Modified antibodies and related compounds, compositions, and methods of use |
WO2014197871A2 (en) | 2013-06-06 | 2014-12-11 | Igenica Biotherapeutics, Inc. | Antibody-drug conjugates, compositions and methods of use |
ES2891755T3 (es) | 2013-06-06 | 2022-01-31 | Pf Medicament | Anticuerpos anti-C10orf54 y utilizaciones de los mismos |
US9545451B2 (en) | 2013-08-21 | 2017-01-17 | Regeneron Pharmaceuticals, Inc. | Anti-PRLR antibodies and methods for killing PRLR-expressing cells |
EA038192B1 (ru) | 2013-08-26 | 2021-07-21 | Регенерон Фармасьютикалз, Инк. | Фармацевтические композиции, содержащие диастереомеры макролида, способы их синтезирования и терапевтическое применение |
CA3178867A1 (en) | 2013-11-27 | 2015-06-04 | Redwood Bioscience, Inc. | Hydrazinyl-pyrrolo compounds and methods for producing a conjugate |
WO2015081857A1 (en) | 2013-12-02 | 2015-06-11 | Hong Kong Baptist University | Anticancer maytansinoids with two fused macrocyclic rings |
WO2015187596A2 (en) | 2014-06-02 | 2015-12-10 | Regeneron Pharmaceuticals, Inc. | Biologically active molecule conjugates, reagents and methods of manufacture, and therapeutic uses |
WO2016160615A1 (en) | 2015-03-27 | 2016-10-06 | Regeneron Pharmaceuticals, Inc. | Maytansinoid derivatives, conjugates thereof, and methods of use |
EA039072B9 (ru) | 2016-01-25 | 2022-02-04 | Регенерон Фармасьютикалз, Инк. | Производные майтанзиноида, их конъюгаты и способы применения |
-
2014
- 2014-08-26 EA EA201600191A patent/EA038192B1/ru unknown
- 2014-08-26 SG SG11201601230RA patent/SG11201601230RA/en unknown
- 2014-08-26 CN CN201480047607.3A patent/CN105530942B/zh active Active
- 2014-08-26 JP JP2016537780A patent/JP6608823B2/ja active Active
- 2014-08-26 CA CA2921412A patent/CA2921412A1/en active Pending
- 2014-08-26 KR KR1020167008038A patent/KR102252925B1/ko active IP Right Grant
- 2014-08-26 EP EP14766580.6A patent/EP3038624A1/en active Pending
- 2014-08-26 US US14/913,965 patent/US20160354482A1/en not_active Abandoned
- 2014-08-26 AU AU2014311361A patent/AU2014311361B2/en active Active
- 2014-08-26 MX MX2016002149A patent/MX2016002149A/es active IP Right Grant
- 2014-08-26 WO PCT/US2014/052757 patent/WO2015031396A1/en active Application Filing
- 2014-08-26 BR BR112016004023A patent/BR112016004023A2/pt not_active Application Discontinuation
-
2016
- 2016-02-21 IL IL244203A patent/IL244203B/en active IP Right Grant
- 2016-02-23 CL CL2016000408A patent/CL2016000408A1/es unknown
- 2016-02-26 PH PH12016500380A patent/PH12016500380A1/en unknown
- 2016-03-04 ZA ZA2016/01534A patent/ZA201601534B/en unknown
- 2016-07-12 HK HK16108121.7A patent/HK1220115A1/zh unknown
-
2018
- 2018-11-13 US US16/189,925 patent/US11596635B2/en active Active
-
2022
- 2022-12-22 US US18/145,811 patent/US20230321109A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
PH12016500380A1 (en) | 2016-05-16 |
NZ756518A (en) | 2021-10-29 |
US11596635B2 (en) | 2023-03-07 |
EP3038624A1 (en) | 2016-07-06 |
CL2016000408A1 (es) | 2017-02-24 |
CA2921412A1 (en) | 2015-03-05 |
CN105530942B (zh) | 2019-10-11 |
NZ716768A (en) | 2021-10-29 |
EA201600191A1 (ru) | 2016-07-29 |
EA201600191A8 (ru) | 2018-04-30 |
US20230321109A1 (en) | 2023-10-12 |
JP6608823B2 (ja) | 2019-11-20 |
HK1220115A1 (zh) | 2017-04-28 |
ZA201601534B (en) | 2023-11-29 |
AU2014311361A1 (en) | 2016-03-03 |
JP2016528304A (ja) | 2016-09-15 |
MX2016002149A (es) | 2016-10-28 |
CN105530942A (zh) | 2016-04-27 |
KR102252925B1 (ko) | 2021-05-18 |
BR112016004023A2 (pt) | 2022-11-16 |
WO2015031396A1 (en) | 2015-03-05 |
KR20160045146A (ko) | 2016-04-26 |
EA038192B1 (ru) | 2021-07-21 |
IL244203B (en) | 2018-12-31 |
AU2014311361B2 (en) | 2018-11-29 |
US20160354482A1 (en) | 2016-12-08 |
US20190151323A1 (en) | 2019-05-23 |
IL244203A0 (en) | 2016-04-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1220115A1 (zh) | 包含大環內酯類非對映異構體的藥物組合物、其製備方法和治療用途 | |
IL285390A (en) | Arylquinazolines, their preparation and pharmaceutical preparations containing them | |
HK1220980A1 (zh) | 用於治療龐貝氏症的方法和組合物 | |
EP2981611A4 (en) | ANTIBIOTICUM PROTOCOLS AND PHARMACEUTICAL FORMULATIONS AND TREATMENT METHODS THEREWITH | |
IL240876B (en) | History of aminopurine, their preparation and pharmaceutical preparations containing them | |
IL240290A0 (en) | History of pyridazinone-amide and pharmaceutical preparations containing them | |
IL243608A0 (en) | Substances with antiviral activity, preparations containing them and their uses | |
SG11201507347QA (en) | Pharmaceutical composition of s-ketamine hydrochloride | |
IL242347B (en) | Macrocyclic compounds, their preparation and pharmaceutical compositions containing them | |
SG10201912735TA (en) | Pharmaceutical composition of s-ketamine hydrochloride | |
HK1220920A1 (zh) | 治療性組合物和其用途 | |
SG11201601047SA (en) | Derivatives of uncialamycin, methods of synthesis and their use as antitumor agents | |
IL243733A0 (en) | Cyclopentane history, their preparation and medicines containing them | |
HK1211021A1 (en) | 2-substituted-6-biarylmethylamino-9-cyclopentyl-9h-purine derivatives, use thereof as medicaments, and pharmaceutical compositions 2--6--9--9h- | |
IL246406A0 (en) | History of imidazopyrazinone, their preparation and pharmaceutical preparations containing them | |
ZA201802033B (en) | Heteroaryl compounds and their use as therapeutic drugs | |
IL239054B (en) | History of azaquinazoline carboxamide, their preparation and pharmaceutical preparations containing them | |
IL243227B (en) | History of diaminocyclopentane carboxamide, their preparation and pharmaceutical preparations containing them | |
IL246298A0 (en) | History of piperidine, their preparation and pharmaceutical preparations containing them | |
IL239873A0 (en) | The history of piperidinylcarbazole, their preparation and pharmaceutical preparations containing them | |
HK1209127A1 (en) | Macrolide derivatives, preparation thereof and therapeutic use thereof |